Veraxa Biotech AG(VRXA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | 7.7 | EPS (ttm) | 0.21 | Insider Own | 75.11% | Shs Outstand | 147.7M | Perf Week | 19.57% |
| Market Cap | 0.24B | Forward P/E | - | EPS next Y | - | Insider Trans | 0.05% | Shs Float | 36.8M | Perf Month | -12.7% |
| Enterprise Value | 0.24B | PEG | - | EPS next Q | - | Inst Own | 0.33% | Short Float | 1.03% | Perf Quarter | -90.36% |
| Income | 0.01B | P/S | - | EPS this Y | - | Inst Trans | 33.67% | Short Ratio | 0.67 | Perf Half Y | -86.46% |
| Sales | 0.00B | P/B | - | EPS next 5Y | - | ROA | 2.52% | Short Interest | 0.38M | Perf YTD | -84.54% |
| Book/sh | -2.25 | P/C | 8125.47 | EPS past 3/5Y | - | ROE | 5.72% | 52W High | -93.97% ($27.36) | Perf Year | -84.18% |
| Cash/sh | 0 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 29.92% ($1.27) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 2.24% | Gross Margin | - | Volatility(W/M) | 16.86% 11.21% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.25 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0 | EPS Q/Q | -91.03% | Profit Margin | - | RSI (14) | 43.56 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 0 | Sales Q/Q | - | SMA20 | -0.93% ($1.67) | Beta | 0.04 | Target Price | - |
| Payout | - | Debt/Eq | - | Earnings | - | SMA50 | -13.03% ($1.9) | Rel Volume | 0.7 | Prev Close | $1.59 |
| Employees | 3 | LT Debt/Eq | - | EPS/Sales Surpr. | - | SMA200 | -80.93% ($8.65) | Avg Volume(3M) | 0.57M | Price | $1.65 |
| IPO | 2024/9/30 | Option/Short | No/Yes | Trades | 539 | Volume | 400,070 | Change | 3.77% |
Company
VRXA is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 A global clinical-stage biotech company developing next-generation antibody-based cancer therapeutics and antibody-drug conjugates (ADCs). Headquartered in Switzerland, it is building an innovative oncology pipeline based on a platform technology that selectively targets tumor sites to reduce side effects.
Over the past 1 year, on the lower side
94% below its 1-year high.
VRXA has weak earning power
Tap to view numbers
The price looks about right
Trading at 7.7 times earnings.
Tap to view numbers
Holding long would have lost money
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 0.3%.
Tap to view numbers
It ranks #4 in the industry
Based on market cap of $244M.
VRXA $244M PER 7.7
VRTX $130B PER 29.9
REGN $82B PER 19.6
ARGX $62B PER 37.5
FAQ
What kind of company is VRXA?
VRXA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of VRXA?
The market cap of VRXA is approximately $244M, ranking 3,935 within its sector.
What is the P/E ratio of VRXA?
VRXA has a P/E ratio of approximately 7.7x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for VRXA?
VRXA has recorded a 52-week high of $27.36 and a low of $1.27.
